Stock FLAG.U FIRST LIGHT ACQUISITION GROUP, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases First Light Acquisition Group, Inc. Nyse

Equities

FLAG.U

US3207032000

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board
GL
Calidi to Effect Reverse Stock Split
AQ
Calidi to Effect Reverse Stock Split
BU
Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors
BU
Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13
BU
Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors
BU
Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting
BU
 Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
BU
Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results
BU
Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
BU
Join Calidi Biotherapeutics Exclusive Live Investor Webinar and Q&A Session on April 24
AQ
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24
BU
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
BU
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
BU
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company's Novel Immunotherapies at the AACR Annual Meeting 2024
AQ
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024
BU
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results
BU
Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer
BU
Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference
BU
Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLDI Stock
  4. FLAG.U Stock
  5. News First Light Acquisition Group, Inc.
  6. Press Releases